Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2848-2854

  Skiadas, Ioannis ^a,b   Pefanis, Angelos ^a   Papalois, Apostolos ^c   Kyroudi, Aspasia ^a   Triantafyllidi, Helen ^a   Tsaganos, Thomas ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c ELPEN Research Experimental Centre   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; DEXAMETHASONE; MOXIFLOXACIN; OXACILLIN; PENICILLIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; CALCIFICATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; FIBROBLAST; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HISTOPATHOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RABBIT; RELAPSE; STAPHYLOCOCCUS AUREUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; AORTIC VALVE; AZA COMPOUNDS; DEXAMETHASONE; ECHOCARDIOGRAPHY; ENDOCARDITIS, BACTERIAL; HUMANS; METHICILLIN; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 34547619978     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01376-06     Document Type: Article

References (35)

1. Andes, D. R., and W. A. Craig. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin. Infect. Dis. 27:47-50.
2. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 111:e394-e434. doi: 10.1161/circulationaha. 105.165564.
3. Barnes, P. J. 2006. Corticosteroids, the drugs to beat. Eur. J. Pharmacol. 533:2-14.
4. Belenkie, I., and A. Rademaker. 1981. Acute and chronic changes after aortic valve damage in the intact dog. Am. J. Physiol. 241:H95-H103.
5. Bonow, R. O., B. A. Carabello, K. Chatterjee, A. C. de Leon, Jr., D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, R. A. O'Rourke, C. M. Otto, P. M. Shah, J. S. Shanewise, et al. 1 August 2006. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J. Am. Coll. Cardiol. 48:e1-e148. doi:10.1016/j.jacc.2006.05. 021.
6. Coghlan, M. J., S. W. Elmore, P. R. Kym, and M. E. Kort. 2003. The pursuit of differentiated ligands for the glucocorticoid receptor. Curr. Top. Med. Chem. 3:1617-1635.
7. Dajcs, J. J., B. A. Thibodeaux, M. E. Marquart, D. O. Girgis, M. Traidej, and R. J. O'Callaghan. 2004. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob. Agents Chemother. 48:1948-1952.
8. Entenza, J. M., Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon. 2001. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob. Agents Chemother. 45:3076-3083.
9. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. M. van der Meer, T. S. J. Elliott, D. P. Levine, and A. S. Bayer. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021.
10. Francioli, P. B., and L. R. Freedman. 1979. Streptococcal infection of endocardial and other intravascular vegetations in rabbits: natural history and effect of dexamethasone. Infect. Immun. 24:483-491.
11. Giamarellou, H. 2002. Nosocomial cardiac infections. J. Hosp. Infect. 50:91-105.
12. Kan, H., and M. S. Finkel. 2003. Inflammatory mediators and reversible myocardial dysfunction. J. Cell. Physiol. 195:1-11.
13. Keating, G. M., and L. J. Scott. 2004. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 64:2347-2377.
14. Leibovich, S. J., and R. Ross. 1975. The role of the macrophage in wound repair: a study with hydrocortisone and antimacrophage serum. Am. J. Pathol. 78:71-100.
15. Le Moing, V., F. Lacassin, M. Delahousse, X. Duval, P. Longuet, C. Leport, and J. L. Vilde. 1998. Use of corticosteroids in glomerulonephritis related to infective endocarditis: three cases and review. Clin. Infect. Dis. 28:1057-1061.
16. Lewis, R. P., and H. Sandler. 1971. Relationship between changes in left ventricular dimension and the ejection fraction in man. Circulation 44:548-557.
17. Liang, H., M. B. Kays, and K. S. Sowinski. 2002. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 772:53-63.
18. McDonald, I. G. 1976. Echocardiography assessment of left ventricular function in aortic valve disease. Circulation 53:860-864.
19. McIntyre, P. B., C. S. Berkey, S. M. King, U. B. Schaad, T. Kilpi, G. Y. Kanra, and C. M. Perez. 1997. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 278:925-931.
20. Moreillon, P., Y. Que, and A. Bayer. 2002. Pathogenesis of streptococcal and staphylococcal endocaditis. Infect. Dis. Clin. N. Am. 16:297-318.
21. Murray, R. J. 2005. Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Intern. Med. J. 2(Suppl 35):S25-S44.
22. Østergaard, C., T. K. Sørensen, J. D. Knudsen, and N. Frimodt-Møller. 1998. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. 42:1706-1712.
23. Perez, J. R., S. Shull, and G. L. Gendimenico. 1992. Glucocorticoid and retinoid regulation of alpha-2 type I procollagen promoter activity. J. Cell. Biochem. 50:26-34.
24. Rappaport, J. M., S. M. Bhatt, R. F. Burkard, S. N. Merchant, and J. B. Nadol, Jr. 1999. Prevention of hearing loss in experimental pneumococcal meningitis by administration of dexamethasone and ketorolac. J. Infect. Dis. 179:264-268.
25. Sakiniene, E., T. Bremell, and A. Tarkowski. 1996. Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum. 39:1596-1605.
26. Siaperas, P., A. Pefanis, D. Iliopoulos, I. Katsarolis, A. Kyroudi-Voulgari, I. Donta, P. Karayiannakos, and H. Giamarellou. 2001. Evidence of less severe valve destruction after treatment of experimental endocarditis with vancomycin and dexamethasone. Antimicrob. Agents Chemother. 45:3531-3537.
27. Smith, M. A., J. A. Sorenson, G. D'Aversa, S. Mandelbaum, I. Udell, and W. Harrison. 1997. Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. J. Infect. Dis. 175:462-466.
28. Syrogiannopoulos, G. A., K. D. Olsen, J. S. Reisch, and G. H. McCracken, Jr. 1987. Dexamethasone in the treatment of Haemophilus influenzae type b meningitis. J. Infect. Dis. 155:213-219.
29. van der Goes, A., K. Hoekstra, T. K. van den Berg, and C. D. Dijkstra. 2000. Dexamethasone promotes phagocytosis and bacterial killing by human monocytes/macrophages in vitro. J. Leukoc. Biol. 67:801-807.
30. Veltrop, M. H. A. M., M. J. L. M. F. Bancsi, R. M. Bertina, and J. Thompson. 2000. Role of monocytes in experimental Staphylococcus aureus endocarditis. Infect. Immun. 68:4818-4821.
31. Verba, V., E. Sakiniene, and A. Tarkowski. 1997. Beneficial effect of glucocorticoids on the course of haematogenously acquired Staphylococcus aureus nephritis. Scand. J. Immunol. 45:282-286.
32. Watanakunakorn, C., and T. Burkert. 1993. Infective endocarditis at a large community hospital, 1980-1990: a review of 210 episodes. Medicine 72:90-102.
33. Wise, R., J. Andrews, G. Marshall, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43:1508-1510.
34. Witte, M. B., and A. Barbul. 1997. Wound healing. Surg. Clin. N. Am. 77:509-528.
35. Xiong, Y.-Q., L. I. Kupferwasser, P. M. Zack, and A. S. Bayer. 1999. Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob. Agents Chemother. 43:1737-1742.